EVGN
HEALTHCAREEvogene Ltd
$0.79+0.02 (+2.67%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving EVGN Today?
No stock-specific AI insight has been generated for EVGN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.72$2.42
$0.79
Fundamentals
Market Cap$10M
P/E Ratio—
EPS$-1.70
Dividend Yield—
Dividend / Share—
ROE-1.0%
Profit Margin-2.2%
Debt / Equity—
Trading
Volume92K
Avg Volume (10D)—
Shares Outstanding12.1M
EVGN News
21 articles- Evogene will discuss first-quarter results on a May 20 Zoom callStock Titan·May 7, 2026
- Evogene Schedules First Quarter 2026 Financial Results ReleasePR Newswire·May 7, 2026
- Evogene Reports Receipt of Nasdaq Minimum Bid Price NotificationYahoo Finance·Apr 2, 2026
- Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel FeedstockYahoo Finance·Mar 31, 2026
- Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue DeclineYahoo Finance·Mar 14, 2026
- Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026Yahoo Finance·Mar 9, 2026
- Evogene Ltd. Q4 2025 Earnings Call SummaryMoby·Mar 6, 2026
- Evogene: Q4 Earnings SnapshotYahoo Finance·Mar 5, 2026
- Evogene Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 5, 2026
- Evogene Releases CEO Letter to ShareholdersYahoo Finance·Feb 25, 2026
- Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results ReleaseYahoo Finance·Feb 19, 2026
- Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer TherapeuticsYahoo Finance·Feb 17, 2026
- Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory DiseasesYahoo Finance·Feb 11, 2026
- Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross ProceedsYahoo Finance·Feb 10, 2026
- Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™Yahoo Finance·Feb 10, 2026
- Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory BoardYahoo Finance·Feb 9, 2026
- Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung CancerYahoo Finance·Feb 5, 2026
- Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating DisordersYahoo Finance·Jan 7, 2026
- Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business DevelopmentYahoo Finance·Dec 30, 2025
- Evogene: Q3 Earnings SnapshotYahoo Finance·Nov 20, 2025
- Evogene Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 20, 2025
All 21 articles loaded
Price Data
Open$0.76
Previous Close$0.77
Day High$0.80
Day Low$0.75
52 Week High$2.42
52 Week Low$0.72
52-Week Range
$0.72$2.42
$0.79
Fundamentals
Market Cap$10M
P/E Ratio—
EPS$-1.70
Dividend Yield—
Dividend / Share—
ROE-1.0%
Profit Margin-2.2%
Debt / Equity—
Trading
Volume92K
Avg Volume (10D)—
Shares Outstanding12.1M
About Evogene Ltd
Evogene Ltd., is a computational biology company. The company is headquartered in Rehovot, Israel.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—